Daurismo (glasdegib) is a targeted cancer medication that’s used to treat a blood cancer called acute myeloid leukemia (AML). It’s specifically used for adults who are older than 75 years or for those who can’t tolerate high-intensity chemotherapy. Daurismo (glasdegib) is a tablet that you take by mouth, but it can cause side effects such as muscle spasms and changes in heart rhythm. This medication is very harmful to an unborn baby, so people who can get pregnant must use reliable birth control during treatment.
Newly-diagnosed acute myeloid leukemia (AML), given with low-dose cytarabine (Ara-C) chemotherapy, in:
Adults who are 75 years of age or older
Adults who have other health problems that prevent them from receiving intensive chemotherapy
Your body uses many pathways, such as the Hedgehog pathway, to send signals to your cells to help the cells grow. In cancers like leukemia, the Hedgehog pathway becomes overactive, leading to cancer growth.
When the Hedgehog pathway doesn't work as it normally should, it also seems to help leukemia cells outsmart some chemotherapy treatments. In other words, this pathway helps the cancer become drug resistant.
Daurismo (glasdegib) is a Hedgehog pathway inhibitor. By blocking the Hedgehog pathway, the medication slows cancer growth.
Blocking the pathway also helps prevent drug resistance and allows other leukemia medications like cytarabine (Ara-C) to work better. When Daurismo (glasdegib) is used with cytarabine, the two medications work together to fight the cancer.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Taken by mouth
An option for people who can’t take intensive chemotherapy
Works in a more specific, targeted way than traditional chemotherapy
Can cause muscle spasms and taste changes
Might interact with other medications (like antiarrhythmics and certain antibiotics)
Very unsafe for pregnant women
You can take Daurismo (glasdegib) with or without food. Take the medication at the same time each day, and swallow the tablets whole. Don’t crush or split the tablets.
If you forget to take a dose of Daurismo (glasdegib) and it’s more than 12 hours until your next dose, take it as soon as you remember. But if your next dose is less than 12 hours away, skip the missed dose and take your next dose as you usually would.
Check your body temperature regularly, ideally once a day. Call your provider if your temperature is 100.4 degrees Fahrenheit or higher; this means that you have a fever. Your provider will want to check to see whether you have a condition called neutropenic fever (a fever that happens when your white blood cell counts are low), which can sometimes be serious.
Daurismo (glasdegib) can change the way things taste. If things don’t taste the way you expect them to, your appetite for those foods might also change. Sometimes, changing the amount of salt or spices in your food can help. It might also be helpful to meet with a dietician experienced in helping people with cancer to find ideas for what you can eat.
Don’t donate blood, blood products, or semen while you’re taking Daurismo (glasdegib) and for at least 30 days after the last dose. It’s possible for females who can become pregnant to be given donated blood products containing the medication, which can be harmful to unborn babies.
Ask your provider about the best way to safely handle Daurismo (glasdegib) and throw away any leftover medication. You might be able to bring it to their office or clinic for proper disposal. It’s important to be extra careful with Daurismo (glasdegib) because cancer medications can be harmful to people who handle or come in contact with them. Keep the medication up and away, so children and pets won’t be able to reach it.
Daurismo (glasdegib) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Results from animal studies suggest that Daurismo (glasdegib) can cause serious harm or death to an unborn baby. For this reason, pregnant women shouldn’t take this medication. If you’re able to have children, you must confirm that you’re not pregnant (a negative pregnancy test result) before you start Daurismo (glasdegib).
Use effective birth control while you’re taking Daurismo (glasdegib) and for at least 30 days after the last dose. And men who are taking Daurismo (glasdegib) and have partners who can have children should also use condoms, even after a vasectomy. Continue using these birth control methods for at least 30 days after the last dose.
Risk factors: Heart failure | History of abnormal heart rhythms | Abnormal electrolyte levels | Taking other medications that can affect heart rhythm
Some people taking Daurismo (glasdegib) have had changes in the electrical activity of their heart, leading to abnormal heart rhythms that can be life-threatening. You might be at higher risk if you were born with heart rhythm problems (e.g., long QT syndrome), if you have heart failure, or if you’re taking other medications that can affect heart rhythm.
To check your risk for these heart problems, your provider will monitor your heart rhythm with a test called an electrocardiogram (ECG or EKG). Your provider will also order blood tests to check your electrolyte levels because abnormal levels can affect your heart rhythm. You might need ECGs and lab tests more often if you’re at high risk for heart rhythm problems. Seek medical help right away if you have sudden chest pain, have an irregular heartbeat, feel very dizzy, or pass out; these can be signs of abnormal heart rhythm.
Some people have had muscle problems such as muscle pain and muscle spasms while they were taking Daurismo (glasdegib). These side effects are most commonly mild, but it’s possible that they could be severe. Sometimes, people also had higher creatine phosphokinase (CPK) levels in their blood, which can suggest muscle damage.
Let your provider know if you have muscle pain, cramping, or spasms. Your provider might recommend stretching to relieve the pain. Your provider might also order blood tests to check your CPK levels and electrolyte levels (abnormal electrolyte levels can also cause muscle symptoms). Depending on how severe your muscle side effects are, it’s possible you’ll need to pause treatment, take a lower dose of Daurismo (glasdegib), or stop taking the medication altogether.
The typical dose is 100 mg by mouth once a day. Daurismo (glasdegib) is taken every day during each 28-day treatment cycle.
Daurismo (glasdegib) is taken together with a low dose of a chemotherapy medication called cytarabine, which is given as an injection on days 1 to 10 of the 28-day treatment cycle.
Newly-diagnosed acute myeloid leukemia (AML), given with low-dose cytarabine (Ara-C) chemotherapy, in:
Adults who are 75 years of age or older
Adults who have other health problems that prevent them from receiving intensive chemotherapy
Acute myeloid leukemia (AML) in older adults or people with certain medical conditions
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults
Acute myeloid leukemia (AML) treatment
Acute lymphoblastic leukemia (ALL) treatment
Chronic myeloid leukemia (CML) treatment
Meningeal leukemia treatment and prevention - if given intrathecally
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
American Cancer Society. (2019). Chemotherapy safety.
American Cancer Society. (2021). How targeted therapies are used to treat cancer.
Cortes, J. E., et al. (2018). Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. American Journal of Hematology.
Farzam, K., et al. (2023). QT prolonging drugs. StatPearls.
Iver, S. G., et al. (2022). Profile of glasdegib for the treatment of newly diagnosed acute myeloid leukemia (AML): Evidence to date. Cancer Management and Research.
Lainez-González, D., et al. (2021). Understanding the hedgehog signaling pathway in acute myeloid leukemia stem cells: A necessary step toward a cure. Biology.
MedlinePlus. (2023). Creatine phosphokinase test.
National Cancer Institute. (2016). Why do cancer treatments stop working? Overcoming treatment resistance.
National Cancer Institute. (2022). Targeted therapy to treat cancer.
National Cancer Institute. (2023). Acute myeloid leukemia treatment (PDQ®)–Patient version.
National Center for Complementary and Integrative Health. (2020). St. John’s wort.
National Comprehensive Cancer Network. (2021). Anemia and neutropenia: Low red and white blood cell counts.
National Heart, Lung, and Blood Institute. (2022). Long QT syndrome.
Nguyen, N. M., et al. (2022). Hedgehog pathway inhibitors as targeted cancer therapy and strategies to overcome drug resistance. International Journal of Molecular Sciences.
Olivero J. J., Sr. (2016). Cardiac consequences of electrolyte imbalance. Methodist DeBakey Cardiovascular Journal.
Patel, K., et al. (2017). Febrile neutropenia. Journal of the American Medical Association Oncology.
Pfizer Laboratories Div Pfizer Inc. (2023). Daurismo- glasdegib tablet, film coated [package insert]. DailyMed.
Relias, V., et al. (2021). Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists. Journal of Oncology Pharmacy Practice.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.